S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
66,000% upside on tiny biotech? (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
MarketBeat Week in Review – 9/25 - 9/29
66,000% upside on tiny biotech? (Ad)
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
66,000% upside on tiny biotech? (Ad)
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
California Gov. Gavin Newsom rejects bill that would have given unemployment checks to some striking workers
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
66,000% upside on tiny biotech? (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
MarketBeat Week in Review – 9/25 - 9/29
66,000% upside on tiny biotech? (Ad)
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
66,000% upside on tiny biotech? (Ad)
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
California Gov. Gavin Newsom rejects bill that would have given unemployment checks to some striking workers
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
66,000% upside on tiny biotech? (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
MarketBeat Week in Review – 9/25 - 9/29
66,000% upside on tiny biotech? (Ad)
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
66,000% upside on tiny biotech? (Ad)
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
California Gov. Gavin Newsom rejects bill that would have given unemployment checks to some striking workers
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
66,000% upside on tiny biotech? (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
MarketBeat Week in Review – 9/25 - 9/29
66,000% upside on tiny biotech? (Ad)
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
66,000% upside on tiny biotech? (Ad)
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
California Gov. Gavin Newsom rejects bill that would have given unemployment checks to some striking workers
Top-Rated StocksTop-Rated
NASDAQ:IMCR

Immunocore (IMCR) Stock Forecast, Price & News

$51.90
+0.78 (+1.53%)
(As of 09/29/2023 ET)
Compare
Today's Range
$50.71
▼
$52.36
50-Day Range
$49.50
▼
$66.60
52-Week Range
$44.79
▼
$69.06
Volume
243,736 shs
Average Volume
267,303 shs
Market Capitalization
$2.54 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$71.38
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

Immunocore MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.92 Rating Score
Upside/​Downside
37.5% Upside
$71.38 Price Target
Short Interest
Bearish
6.86% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.04mentions of Immunocore in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.35) to ($1.45) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.98 out of 5 stars

Medical Sector

641st out of 972 stocks

Biological Products, Except Diagnostic Industry

95th out of 152 stocks

See Top Rated MarketRank™ Stocks Here

IMCR stock logo

About Immunocore (NASDAQ:IMCR) Stock

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also developing other programs for oncology comprise tebentafusp that is in Phase 2/3 clinical trial in patients with advanced melanoma; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising cutaneous melanoma, ovarian, non-small cell lung cancer, and endometrial; IMC-T119C for multiple solid tumor cancers; IMC-P115C for multiple solid tumor cancers; and IMC-R117C, which is for a range of tumors, including colorectal, gastro-esophageal, and pancreatic cancers. In addition, the company's programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in Phase 1 clinical trial for patients with human immunosuppression virus. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

IMCR Price History

IMCR Stock News Headlines

September 7, 2023 | marketbeat.com
Institutions are Buying These 3 Stocks and Analysts Agree (IMCR)
Rumble (RUM), Immunocore (IMCR), and STMicroelectronics (STM) are attracting increased institutional interest, presenting potential investment opportunities.
September 28, 2023 | americanbankingnews.com
Immunocore (NASDAQ:IMCR) and Bio-Techne (NASDAQ:TECH) Critical Review
October 1, 2023 | Chaikin Analytics (Ad)
This Stock Could Go Up 66% or More.
Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023.  Click here to get his latest buy.  More here.
September 23, 2023 | americanbankingnews.com
Immunocore (NASDAQ:IMCR) PT Raised to $85.00 at Oppenheimer
September 22, 2023 | msn.com
Cardlytics, Immunocore See Activist Action
September 22, 2023 | americanbankingnews.com
Immunocore (NASDAQ:IMCR) Trading 2.8% Higher After Analyst Upgrade
September 13, 2023 | msn.com
Needham Initiates Coverage of Immunocore Holdings plc - ADR (IMCR) with Buy Recommendation
September 13, 2023 | markets.businessinsider.com
Analyst Expectations for Immunocore Hldgs's Future
October 1, 2023 | Porter and Company (Ad)
Elon Bets Big On Controversial Energy Tech: "This Is Bigger Than AI"
If this tech goes mainstream, it could destroy the oil and gas industry, the clean energy sector, and the billionaires who profit from it…
September 13, 2023 | markets.businessinsider.com
Cancer Focused Immunocore Leads The Way In TCR Therapeutics, Positioned For Success: Analyst Says
August 23, 2023 | markets.businessinsider.com
H.C. Wainwright Sticks to Its Buy Rating for Immunocore Holdings (IMCR)
August 16, 2023 | msn.com
Capital One Initiates Coverage of Immunocore Holdings plc - ADR (IMCR) with Overweight Recommendation
August 13, 2023 | finance.yahoo.com
Immunocore Holdings plc (NASDAQ:IMCR) Q2 2023 Earnings Call Transcript
August 11, 2023 | msn.com
Oppenheimer Maintains Immunocore Holdings plc - ADR (IMCR) Outperform Recommendation
August 11, 2023 | msn.com
BTIG Maintains Immunocore Holdings plc - ADR (IMCR) Buy Recommendation
August 10, 2023 | finanznachrichten.de
Immunocore Holdings Limited: Immunocore Reports Second Quarter 2023 Financial Results and Provides Business Update
August 10, 2023 | finance.yahoo.com
Immunocore Reports Second Quarter 2023 Financial Results and Provides Business Update
August 9, 2023 | benzinga.com
Immunocore Hldgs's Earnings Outlook
August 8, 2023 | finance.yahoo.com
Why Earnings Season Could Be Great for Immunocore (IMCR)
August 3, 2023 | finance.yahoo.com
Immunocore to report second quarter 2023 financial results and host call on August 10, 2023
July 18, 2023 | finance.yahoo.com
Immunocore Holdings (NASDAQ:IMCR) shareholders have earned a 41% return over the last year
July 17, 2023 | msn.com
Canaccord Genuity Initiates Coverage of Immunocore Holdings plc - ADR (IMCR) with Hold Recommendation
June 29, 2023 | markets.businessinsider.com
Analysts Offer Insights on Healthcare Companies: Roche Holding AG (OtherRHHVF) and Immunocore Holdings (IMCR)
June 26, 2023 | markets.businessinsider.com
Analysts Have Conflicting Sentiments on These Healthcare Companies: Immunocore Holdings (IMCR), Walgreens Boots Alliance (WBA) and Genmab (GMAB)
June 20, 2023 | markets.businessinsider.com
Goldman Sachs Sticks to Its Buy Rating for Immunocore Holdings (IMCR)
June 13, 2023 | fool.com
Immunocore Plc (NASDAQ: IMCR)
June 13, 2023 | markets.businessinsider.com
Immunocore Holdings (IMCR) Gets a Buy from Morgan Stanley
See More Headlines
Receive IMCR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Immunocore and its competitors with MarketBeat's FREE daily newsletter.

IMCR Company Calendar

Last Earnings
8/10/2023
Today
10/01/2023
Next Earnings (Estimated)
11/08/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:IMCR
CUSIP
N/A
CIK
1671927
Web
www.immunocore.com
Phone
44-12-3543-8600
Fax
N/A
Employees
408
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$71.38
High Stock Price Forecast
$91.00
Low Stock Price Forecast
$16.00
Forecasted Upside/Downside
+37.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.92
Research Coverage
13 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($1.29)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-50,990,000.00
Net Margins
-27.72%
Pretax Margin
-25.99%
Return on Equity
-17.97%
Return on Assets
-11.54%

Debt

Debt-to-Equity Ratio
0.23
Current Ratio
4.28
Quick Ratio
4.26

Sales & Book Value

Annual Sales
$181.57 million
Price / Sales
13.99
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$7.17 per share
Price / Book
7.24

Miscellaneous

Outstanding Shares
48,941,000
Free Float
46,151,000
Market Cap
$2.54 billion
Optionable
Not Optionable
Beta
0.67
Investing Strategies To Help Grow Your Retirement Income Cover
Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Dr. Bahija Jallal Ph.D. (Age 61)
    CEO & Director
    Comp: $1.42M
  • Mr. Brian R. Di Donato M.B.A. (Age 56)
    CFO & Head of Strategy
  • Ms. Annelise Vuidepot Ph.D.
    CTO and Head of Pipeline & Platform Research
  • Clayton Robertson
    Head of Investor Relations
  • Ms. Lily Margaret Hepworth
    Gen. Counsel & Company Sec.
  • Ms. Amy Judge-Prein
    Chief Compliance Officer
  • Mr. Sébastien Desprez
    Head of Communications
  • Ms. Tina St. Leger (Age 55)
    Chief HR Officer & Director
  • Dr. David Berman M.D. (Age 52)
    Ph.D., Head of R&D
  • Ms. Debra Nielsen
    Chief of Staff

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions













IMCR Stock - Frequently Asked Questions

Should I buy or sell Immunocore stock right now?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Immunocore in the last twelve months. There are currently 1 hold rating and 12 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" IMCR shares.
View IMCR analyst ratings or view top-rated stocks.

What is Immunocore's stock price forecast for 2023?

13 Wall Street research analysts have issued 12 month target prices for Immunocore's stock. Their IMCR share price forecasts range from $16.00 to $91.00. On average, they predict the company's share price to reach $71.38 in the next year. This suggests a possible upside of 37.5% from the stock's current price.
View analysts price targets for IMCR or view top-rated stocks among Wall Street analysts.

How have IMCR shares performed in 2023?

Immunocore's stock was trading at $57.07 at the beginning of 2023. Since then, IMCR shares have decreased by 9.1% and is now trading at $51.90.
View the best growth stocks for 2023 here.

Are investors shorting Immunocore?

Immunocore saw a increase in short interest in the month of September. As of September 15th, there was short interest totaling 3,170,000 shares, an increase of 6.0% from the August 31st total of 2,990,000 shares. Based on an average daily volume of 210,300 shares, the short-interest ratio is currently 15.1 days. Currently, 6.9% of the company's shares are sold short.
View Immunocore's Short Interest.

When is Immunocore's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023.
View our IMCR earnings forecast.

How were Immunocore's earnings last quarter?

Immunocore Holdings plc (NASDAQ:IMCR) issued its earnings results on Thursday, August, 10th. The company reported ($0.37) earnings per share for the quarter, beating analysts' consensus estimates of ($0.40) by $0.03. The business earned $60.70 million during the quarter, compared to analyst estimates of $59.39 million. Immunocore had a negative net margin of 27.72% and a negative trailing twelve-month return on equity of 17.97%.

What ETFs hold Immunocore's stock?

ETFs with the largest weight of Immunocore (NASDAQ:IMCR) stock in their portfolio include ETFMG Treatments Testing and Advancements ETF (GERM), ALPS Medical Breakthroughs ETF (SBIO), Virtus LifeSci Biotech Products ETF (BBP) and Range Cancer Therapeutics ETF (CNCR).BlackRock Future Health ETF (BMED).

When did Immunocore IPO?

(IMCR) raised $199 million in an initial public offering on Friday, February 5th 2021. The company issued 8,300,000 shares at a price of $23.00-$25.00 per share. Goldman Sachs, J.P. Morgan and Jefferies acted as the underwriters for the IPO.

What is Immunocore's stock symbol?

Immunocore trades on the NASDAQ under the ticker symbol "IMCR."

How do I buy shares of Immunocore?

Shares of IMCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Immunocore's stock price today?

One share of IMCR stock can currently be purchased for approximately $51.90.

How much money does Immunocore make?

Immunocore (NASDAQ:IMCR) has a market capitalization of $2.54 billion and generates $181.57 million in revenue each year. The company earns $-50,990,000.00 in net income (profit) each year or ($1.29) on an earnings per share basis.

How many employees does Immunocore have?

The company employs 408 workers across the globe.

How can I contact Immunocore?

Immunocore's mailing address is 92 PARK DRIVE MILTON PARK ABINGDON, OXFORDSHIRE X0, OX14 4RY. The official website for the company is www.immunocore.com. The company can be reached via phone at 44-12-3543-8600 or via email at ir@immunocore.com.

This page (NASDAQ:IMCR) was last updated on 10/1/2023 by MarketBeat.com Staff

My Account -